
Agnieszka Karczmarczyk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2480154/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients. Cancer Management and Research, 2022, Volume 14, 1267-1281.	1.9	0
2	Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma. Cells, 2021, 10, 411.	4.1	7
3	In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia. Oncology Letters, 2021, 21, 285.	1.8	4
4	Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients. Journal of Clinical Medicine, 2021, 10, 867.	2.4	5
5	The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer—A Preliminary Study. International Journal of Molecular Sciences, 2021, 22, 2061.	4.1	8
6	The Predominant Prognostic Significance of NOTCH1 Mutation Defined by Emulsion PCR in Chronic Lymphocytic Leukemia. Cancer Management and Research, 2021, Volume 13, 3663-3674.	1.9	2
7	Prognostic Value of Tie2-Expressing Monocytes in Chronic Lymphocytic Leukemia Patients. Cancers, 2021, 13, 2817.	3.7	3
8	Gene Expression Profiling Predicts Sensitivity of Chronic Lymphocytic Leukemia Cells to Dasatinib. HemaSphere, 2021, 5, e514.	2.7	0
9	An association of circulating Tregs and Th17 cells producing IL-21 and IL-22 with the ROMA in ovarian cancer patients. Cytokine, 2020, 134, 155194.	3.2	2
10	Expression and Clinical Significance of Neuropilin-1 in Patients With Multiple Myeloma. Anticancer Research, 2020, 40, 5437-5443.	1.1	2
11	Cofilin-1 Maintains Prosurvival Signaling in Chronic Lymphocytic Leukemia Cells. Anticancer Research, 2020, 40, 6327-6335.	1.1	0
12	Prognostic impact of NOTCH1 and MYD88 mutations in chronic lymphocytic leukemia patients. Journal of Transfusion Medicine, 2019, 12, 101-108.	0.2	0
13	Zmiany genetyczne w chÅ,oniaku rozlanym z dużych komórek B. Acta Haematologica Polonica, 2019, 50, 204-214.	0.3	1
14	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL—another piece in the puzzle. Annals of Hematology, 2017, 96, 33-50.	1.8	26
15	Prognostic impact of NOTCH1, MYD88 and SF3B1 mutations in Polish population of chronic lymphocytic leukemia patients. Polish Archives of Internal Medicine, 2017, 127, 238-244.	0.4	9
16	Specific cytotoxic Tâ€cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells. British Journal of Haematology, 2016, 174, 582-590.	2.5	3
17	Indirect induction of regulatory T cells accompanies immune responses during peptide vaccination of chronic lymphocytic leukaemia patients. British Journal of Haematology, 2016, 174, 155-157.	2.5	1
18	Accumulation of CD5+CD19+ B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils. Clinical and Experimental Medicine, 2016, 16, 503-509.	3.6	7

#	Article	IF	CITATIONS
19	Detailed Clinical, Immunological and Molecular Analysis of NOTCH1, SF3B1 and MYD88 mutations in Chronic Lymphocytic Leukemia Patients Reveals Accumulation of Negative Prognostic Features in NOTCH1 and SF3B1 mutated Individuals. Blood, 2016, 128, 5570-5570.	1.4	0
20	The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 2908-2913.	1.3	18
21	Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia. Acta Haematologica, 2015, 134, 255-262.	1.4	38
22	Obinutuzumab jako nowa szansa terapeutyczna dla chorych na przewlekÅ,Ä biaÅ,aczkÄ™ limfocytowÄ Acta Haematologica Polonica, 2015, 46, 35-41.	0.3	0
23	The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 435-449.	2.3	183
24	Cytotoxic Activity of Valproic Acid on Primary Chronic Lymphocytic Leukemia Cells. Advances in Clinical and Experimental Medicine, 2015, 24, 55-62.	1.4	6
25	The role of Th17 cells in tumor immunity. Acta Haematologica Polonica, 2014, 45, 155-160.	0.3	3